

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims**

1. (Canceled)
2. (Original) A method of treating metastatic cancer which comprises administering to a patient in need of such treatment a therapeutically effective amount of temozolomide, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, and a therapeutically effective amount of thalidomide, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof.
3. (Amended) The method according to claim 1 or 2, wherein the cancer is ~~primary malignant melanoma or~~ metastatic melanoma.
4. (Canceled)
5. (Canceled)
6. (Amended) The method according to claim 3 or 2, further comprising administering a maintenance dose of thalidomide.
7. (Original) The method according to claim 6, wherein the maintenance dose of thalidomide is 50 to 200 mg/d.
8. (Amended) The method according to claim 3 or 2, wherein the temozolomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 50 to about 250 mg/m<sup>2</sup>, and the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 50 to about 1000 mg.
9. (Original) The method according to claim 8, wherein the temozolomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 50 to about 200 mg/m<sup>2</sup>, and the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 50 to about 750 mg.

10. (Original) The method according to claim 9, wherein the temozolomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 50 to about 200 mg/m<sup>2</sup>, and the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 50 to about 400 mg.

11. (Amended) The method according to claim 1 or 2, wherein the temozolomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of about 75 mg/m<sup>2</sup>/d.

12. (Amended) The method according to claim 1 or 2, wherein the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered at an initial dose of from about 100 to about 200 mg/d.

13. (Amended) The method according to claim 1 or 2, wherein the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered to patient over the age of 70 at an initial dose of from about 50 to about 100 mg/d.

14. (Amended) The method according to claim 1 or 2, wherein the thalidomide, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered prior to the administration of the temozolomide.

15. (Amended) The method according to claim 1 or 2, wherein the thalidomide, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered simultaneously with the administration of the temozolomide.

16. (Amended) The method according to claim 1 or 2, wherein the thalidomide, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered after the administration of the temozolomide.

17. (Amended) The method according to claim 1 or 2, wherein the thalidomide is administered daily and continuously.

18. (Amended) The method according to claim 1-~~or~~ 2, wherein the temozolomide is administered daily and continuously for 6 weeks followed by a rest period.

19. (Amended) The method according to claim 1-~~or~~ 2, wherein the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 50 to about 1000 mg.

20. (Amended) The method according to claim 1-~~or~~ 2, wherein the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 50 to about 400 mg.

21. (Amended) The method according to claim 1-~~or~~ 2, wherein the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 100 to about 200 mg.

22-45. (Canceled)